Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC management, have yet to be established in unresectable HCC, in which the tumor cannot be safely treated via surgical removal.
❓ Unknown
Medical research article - not related to Iran
Just now
November 19, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
This is a medical research article about hepatocellular carcinoma (HCC) treatment and biomarkers, not an article about Iran or Iranian affairs. The article discusses global liver cancer statistics and therapeutic approaches to unresectable HCC.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
Iran rejects unlimited IAEA inspections amid continued military threats
Just now •
Iran's military chief vows retaliation for alleged US attack on Minab school that killed children
12 min ago •